CGD Patients Receiving IFN-γ, Subgroups, Oxidative Function Previous to IFN-γ, and Randomization Dose. The Patient CE Is a Hyperlyonized Carrier of X-Linked CGD Yet Expressing a CGD Phenotype
| Patient/Age/Gender . | CGD Type . | fMLP-Induced CL . | NBT % Pos Cells . | Randomization Dose . |
|---|---|---|---|---|
| AA | A470 | <1% | 0 | High |
| 26/F | ||||
| MA 33/M | A470 | <1% | 0 | High |
| EF | A?0, not specified | <1% | 0 | High |
| 6/F | ||||
| HA | X910 | <1% | 0 | High |
| 17/M | ||||
| CE | X91+ | Minute ∼8% | 4 | High |
| 43/F | ||||
| Hyperlyonized female carrier | ||||
| LG | A670 | <1% | 0 | Low |
| 16/F | ||||
| TW | X910 | <1% | 0 | Low |
| 9/M | ||||
| AW | X910 | <1% | 0 | Low |
| 17/M | ||||
| PA | A470 | <1% | 0 | Low |
| 22/M | ||||
| PE | X910 | <1% | 0 | Low |
| 7/M |
| Patient/Age/Gender . | CGD Type . | fMLP-Induced CL . | NBT % Pos Cells . | Randomization Dose . |
|---|---|---|---|---|
| AA | A470 | <1% | 0 | High |
| 26/F | ||||
| MA 33/M | A470 | <1% | 0 | High |
| EF | A?0, not specified | <1% | 0 | High |
| 6/F | ||||
| HA | X910 | <1% | 0 | High |
| 17/M | ||||
| CE | X91+ | Minute ∼8% | 4 | High |
| 43/F | ||||
| Hyperlyonized female carrier | ||||
| LG | A670 | <1% | 0 | Low |
| 16/F | ||||
| TW | X910 | <1% | 0 | Low |
| 9/M | ||||
| AW | X910 | <1% | 0 | Low |
| 17/M | ||||
| PA | A470 | <1% | 0 | Low |
| 22/M | ||||
| PE | X910 | <1% | 0 | Low |
| 7/M |
Abbreviations: F, female; M, male; X indicates X-linked and A is autosomal recessive inheritance; 91, 47, and 67 indicate the defective “phox” protein; superscript symbols indicate 0, undetectable “phox” protein; +, normal expression of “phox” protein on Western blot (in this case only the expression of her defect gene).